Life Insurance After Cancer in Texas: Waiting Periods, Ratings, and Which Carriers Say Yes

Why cancer history rates so heavily in underwriting

Life insurance mortality tables are built on decades of Society of Actuaries data. Cancer is the second-leading cause of death in the U.S. after heart disease, and recurrence risk varies dramatically by cancer type and stage. Underwriters look at three things: the specific diagnosis (ICD-10 code), the stage at diagnosis, and the number of years since active treatment ended without recurrence. Our how life insurance underwriting works in Texas guide walks through the full evidence file carriers pull.

Two applicants with the same 'cancer history' can land in wildly different rate classes. A 50-year-old with a fully excised basal cell carcinoma from three years ago is essentially non-rated. A 50-year-old with a stage II colon cancer treated four years ago typically lands at Table 2–4 (roughly 150–200% of standard premium), reclassifying to standard around year 7.

Fast-track cancers: standard rates in months, not years

Non-melanoma skin cancers (basal cell, squamous cell) with clean margins are typically underwritten at standard or better rates immediately post-excision, provided no history of melanoma.

Papillary or follicular thyroid cancer, stage I, treated surgically with no recurrence, often qualifies for standard rates within 12 months. Localized (Gleason 6) prostate cancer treated with prostatectomy or radiation frequently qualifies within 1–2 years with a stable PSA.

Ductal carcinoma in situ (DCIS) of the breast — technically stage 0 — is often rated standard within 12–24 months post-treatment when hormone therapy is completed or well-tolerated.

Standard cancers: 2–5 year waiting period

Stage I–II breast, colon, kidney, bladder, and cervical cancers typically require a 2–5 year post-treatment wait before standard or Table 2–4 rates become available. During the wait, most carriers will offer coverage at Table 4–8 (200–400% of standard premium) or decline entirely.

Stage II–III melanoma and Hodgkin/non-Hodgkin lymphoma usually require 3–5 years post-remission with stable follow-up scans. Ratings improve substantially past the 5-year mark and typically reach standard by year 10.

Testicular cancer is unusually favorable: stage I treated by orchiectomy is often standard-rated within 12–24 months given the disease's high cure rate.

Aggressive cancers: long waits or decline

Pancreatic, esophageal, gastric, hepatocellular, glioblastoma, and small-cell lung cancers carry high mortality tables and typically result in a decline for standard fully underwritten term or permanent coverage for 5–10 years post-treatment. Even at 10 years, ratings often stay at Table 6–8.

Stage III–IV cancers of any type usually mean fully underwritten coverage is unavailable for 3–5 years, and heavily table-rated (Table 8+) or declined thereafter. Applicants in this category should focus on graded-benefit and guaranteed-issue alternatives rather than trying to force a standard application.

Guaranteed-issue and graded-benefit alternatives

Every major final-expense carrier in Texas offers guaranteed-issue whole life from $5,000 to $25,000 with no health questions for applicants age 45–85. These policies use a graded death benefit: full face amount pays for accidental death from day one, but non-accidental death in years 1–2 typically returns premiums plus 10% interest rather than the face amount.

Simplified-issue whole life adds a short health questionnaire — typically 8–12 yes/no questions — but no exam. Face amounts run $10,000–$50,000 and the death benefit is usually full from day one for applicants who answer 'no' to all questions.

For cancer survivors within the waiting period who need meaningful coverage, layering a simplified-issue $50,000 policy today with a plan to reapply for fully underwritten coverage at the end of the waiting period is a reasonable bridge.

Which carriers are cancer-friendly in Texas

Prudential and Lincoln National are consistently the most aggressive on early-stage breast, prostate, and thyroid cancers. John Hancock and Protective have specialized underwriting programs for melanoma and lymphoma survivors past year 5.

Mutual of Omaha, AIG, and Transamerica dominate the simplified-issue and guaranteed-issue market for cancer survivors within the waiting period. AAA Life and Gerber Life are competitive on final-expense guaranteed issue.

An independent Texas broker can shop the case blind — sending anonymized medical history to underwriting departments at 8–15 carriers to identify the best offer before a formal application generates an MIB record. A declined application follows you for seven years on the MIB consumer file and can trigger declines from other carriers who see it. Applicants past the waiting period may also qualify for accelerated underwriting or instant issue programs.